| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Emma Fisher, Christopher Eccleston, Louisa Degenhardt, David P Finn, Nanna B Finnerup, Ian Gilron, Simon Haroutounian, Elliot Krane, Andrew S C Rice, Michael Rowbotham, Mark Wallace, R Andrew Moor. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a protocol for an overview of systematic reviews and a systematic review of randomised controlled trials. Pain reports. vol 4. issue 3. 2020-10-01. PMID:31583356. |
cannabinoids, cannabis, and cannabis-based medicine for pain management: a protocol for an overview of systematic reviews and a systematic review of randomised controlled trials. |
2020-10-01 |
2023-08-13 |
human |
| Emma Fisher, Christopher Eccleston, Louisa Degenhardt, David P Finn, Nanna B Finnerup, Ian Gilron, Simon Haroutounian, Elliot Krane, Andrew S C Rice, Michael Rowbotham, Mark Wallace, R Andrew Moor. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a protocol for an overview of systematic reviews and a systematic review of randomised controlled trials. Pain reports. vol 4. issue 3. 2020-10-01. PMID:31583356. |
cannabinoid, cannabis, and cannabis-based medicines (cbms) are thought to reduce pain, but a proliferation of different products has led to variability in trials, creating a challenge when determining the assessment of efficacy in systematic reviews. |
2020-10-01 |
2023-08-13 |
human |
| Emma Fisher, Christopher Eccleston, Louisa Degenhardt, David P Finn, Nanna B Finnerup, Ian Gilron, Simon Haroutounian, Elliot Krane, Andrew S C Rice, Michael Rowbotham, Mark Wallace, R Andrew Moor. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a protocol for an overview of systematic reviews and a systematic review of randomised controlled trials. Pain reports. vol 4. issue 3. 2020-10-01. PMID:31583356. |
we will conduct 2 systematic reviews commissioned by the international association for the study of pain task force on the use of cannabinoids, cannabis, and cbms for pain management: first, an overview review of systematic reviews to summarise the evidence base and second, a systematic review of randomised controlled trials of cannabinoids, cannabis, and cbms. |
2020-10-01 |
2023-08-13 |
human |
| Ian Gilron, Fiona M Blyth, Louisa Degenhardt, Marta Di Forti, Christopher Eccleston, Simon Haroutounian, Andrew Moore, Andrew S C Rice, Mark Wallac. Risks of harm with cannabinoids, cannabis, and cannabis-based medicine for pain management relevant to patients receiving pain treatment: protocol for an overview of systematic reviews. Pain reports. vol 4. issue 3. 2020-10-01. PMID:31583357. |
risks of harm with cannabinoids, cannabis, and cannabis-based medicine for pain management relevant to patients receiving pain treatment: protocol for an overview of systematic reviews. |
2020-10-01 |
2023-08-13 |
Not clear |
| Ian Gilron, Fiona M Blyth, Louisa Degenhardt, Marta Di Forti, Christopher Eccleston, Simon Haroutounian, Andrew Moore, Andrew S C Rice, Mark Wallac. Risks of harm with cannabinoids, cannabis, and cannabis-based medicine for pain management relevant to patients receiving pain treatment: protocol for an overview of systematic reviews. Pain reports. vol 4. issue 3. 2020-10-01. PMID:31583357. |
with the increasing availability of cannabis and cannabinoids and their potential utility for pain treatment, there is a growing need to evaluate the risk-benefit considerations of cannabinoids for the management of pain. |
2020-10-01 |
2023-08-13 |
Not clear |
| Ian Gilron, Fiona M Blyth, Louisa Degenhardt, Marta Di Forti, Christopher Eccleston, Simon Haroutounian, Andrew Moore, Andrew S C Rice, Mark Wallac. Risks of harm with cannabinoids, cannabis, and cannabis-based medicine for pain management relevant to patients receiving pain treatment: protocol for an overview of systematic reviews. Pain reports. vol 4. issue 3. 2020-10-01. PMID:31583357. |
as part of the iasp cannabis and cannabinoids task force, this protocol describes a planned overview of systematic reviews summarizing the risks of harm with cannabinoids that are relevant to patients receiving pain treatment. |
2020-10-01 |
2023-08-13 |
Not clear |
| Gabrielle L McLemore, Kimberlei A Richardso. Data from three prospective longitudinal human cohorts of prenatal marijuana exposure and offspring outcomes from the fetal period through young adulthood. Data in brief. vol 9. 2020-09-30. PMID:27833935. |
the data in this article are in support of our report entitled "prenatal cannabis exposure - the "first hit" to the endocannabinoid system" (k.a. |
2020-09-30 |
2023-08-13 |
human |
| Waqas Jehangir, Michael Stanton, Rafay Khan, Puneet Sahgal, Abdalla Yousi. Did Cannabis Precipitate an STEMI in a Young Woman? Cardiology research. vol 6. issue 3. 2020-09-30. PMID:28197241. |
cannabis is a substance that contains compounds that bind cannabinoid receptors, cb1 and cb2. |
2020-09-30 |
2023-08-13 |
Not clear |
| Waqas Jehangir, Michael Stanton, Rafay Khan, Puneet Sahgal, Abdalla Yousi. Did Cannabis Precipitate an STEMI in a Young Woman? Cardiology research. vol 6. issue 3. 2020-09-30. PMID:28197241. |
delta-9-tetrahydrocannabinol (thc) is the compound in cannabis responsible for its psychoactive effects and binding to cannabinoid receptors. |
2020-09-30 |
2023-08-13 |
Not clear |
| Nikoletta Kalenderoglou, Tara Macpherson, Karen L Wrigh. Cannabidiol Reduces Leukemic Cell Size - But Is It Important? Frontiers in pharmacology. vol 8. 2020-09-30. PMID:28392768. |
the anti-cancer effect of the plant-derived cannabinoid, cannabidiol, has been widely demonstrated both |
2020-09-30 |
2023-08-13 |
Not clear |
| Shreyas Gandhi, Gaurav Vasisth, Anil Kapoo. Systematic review of the potential role of cannabinoids as antiproliferative agents for urological cancers. Canadian Urological Association journal = Journal de l'Association des urologues du Canada. vol 11. issue 3-4. 2020-09-30. PMID:28515817. |
the active components of cannabis sativa (cannabinoids) and their derivatives have received growing interest due to their diverse pharmacological activities, such as cell growth inhibition and tumour regression. |
2020-09-30 |
2023-08-13 |
Not clear |
| Rafael N Ruggiero, Matheus T Rossignoli, Jana B De Ross, Jaime E C Hallak, Joao P Leite, Lezio S Bueno-Junio. Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research. Frontiers in pharmacology. vol 8. 2020-09-30. PMID:28680405. |
in this sense, electrophysiology and viral vector-based circuit dissection, like optogenetics, can further elucidate how exogenous cannabinoids worsen (e.g., tetrahydrocannabinol, thc) or ameliorate (e.g., cannabidiol, cbd) schizophrenia symptoms, like hallucinations, delusions, and cognitive deficits. |
2020-09-30 |
2023-08-13 |
Not clear |
| Mark Henry Alon, Margaret Olibrice Saint-Fleu. Synthetic cannabinoid induced acute respiratory depression: Case series and literature review. Respiratory medicine case reports. vol 22. 2020-09-30. PMID:28794966. |
synthetic cannabinoids are a street drug that is widely attainable and cheap compared to natural cannabis, and has variable potency and unpredictable effects with no commercially available diagnostic test to confirm its presence. |
2020-09-30 |
2023-08-13 |
Not clear |
| Mark Henry Alon, Margaret Olibrice Saint-Fleu. Synthetic cannabinoid induced acute respiratory depression: Case series and literature review. Respiratory medicine case reports. vol 22. 2020-09-30. PMID:28794966. |
similar to natural cannabis, synthetic cannabinoid intoxication can present in several ways with the most common emergency room presentations to be of neurologic and psychiatric manifestation. |
2020-09-30 |
2023-08-13 |
Not clear |
| Binnian Wei, James E McGuffey, Benjamin C Blount, Lanqing Wan. Sensitive Quantification of Cannabinoids in Milk by Alkaline Saponification-Solid Phase Extraction Combined with Isotope Dilution UPLC-MS/MS. ACS omega. vol 1. issue 6. 2020-09-30. PMID:28956022. |
maternal exposure to marijuana during the lactation period-either active or passive-has prompted concerns about transmission of cannabinoids to breastfed infants and possible subsequent adverse health consequences. |
2020-09-30 |
2023-08-13 |
Not clear |
| Kerry Anne Rambaran, Michael Chu, Tyler B Johnson, Saeed K Alzghar. The Current Landscape of Marijuana and Pharmacogenetics. Cureus. vol 9. issue 7. 2020-09-30. PMID:28975060. |
the treatment of medical conditions with cannabis and cannabinoid compounds is advancing. |
2020-09-30 |
2023-08-13 |
Not clear |
| Keane Lim, Yuen Mei See, Jimmy Le. A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 15. issue 4. 2020-09-30. PMID:29073741. |
the discovery of endocannabinoid's role within the central nervous system and its potential therapeutic benefits have brought forth rising interest in the use of cannabis for medical purposes. |
2020-09-30 |
2023-08-13 |
Not clear |
| Eugene L Schar. Translating Endocannabinoid Biology into Clinical Practice: Cannabidiol for Stroke Prevention. Cannabis and cannabinoid research. vol 2. issue 1. 2020-09-30. PMID:29098188. |
translating endocannabinoid biology into clinical practice: cannabidiol for stroke prevention. |
2020-09-30 |
2023-08-13 |
Not clear |
| Eva Martínez-Pinilla, Katia Varani, Irene Reyes-Resina, Edgar Angelats, Fabrizio Vincenzi, Carlos Ferreiro-Vera, Julen Oyarzabal, Enric I Canela, José L Lanciego, Xavier Nadal, Gemma Navarro, Pier Andrea Borea, Rafael Franc. Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB Frontiers in pharmacology. vol 8. 2020-09-30. PMID:29109685. |
binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid cb the mechanism of action of cannabidiol (cbd), the main non-psychotropic component of |
2020-09-30 |
2023-08-13 |
Not clear |
| Andrew M Moon, Sarah A Buckley, Nicholas M Mar. Successful Treatment of Cannabinoid Hyperemesis Syndrome with Topical Capsaicin. ACG case reports journal. vol 5. 2020-09-30. PMID:29379817. |
cannabinoid hyperemesis syndrome (chs) is a clinical entity in which marijuana users develop nausea, vomiting, and abdominal pain that improves with hot water bathing or cannabis cessation. |
2020-09-30 |
2023-08-13 |
Not clear |